cas 1231930-42-9|| where to buy 6-(2-chloro-5-fluoropyrimidin-4-yl)-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole

製品名:6-(2-chloro-5-fluoropyrimidin-4-yl)-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole

IUPAC Name:6-(2-chloro-5-fluoropyrimidin-4-yl)-4-fluoro-2-methyl-1-(propan-2-yl)-1H-1,3-benzodiazole

包装単位	有効在庫	価格（USD）
CM161840-5g	in stock	ȯŪ
CM161840-10g	in stock	ƛǑ
CM161840-25g	in stock	ŪŪŪ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

追記事項

Verification code*

refresh

: CAS番号:1231930-42-9; 分子式:C15H13ClF2N4; 融点:-; SMILESコード:CC1=NC2=C(F)C=C(C3=NC(Cl)=NC=C3F)C=C2N1C(C)C; 密度:

: カタログ番号:CM161840; 分子量:322.74; 沸点:; MDL番号:MFCD25977328; 保管方法:Keep in inert atmosphere, store at 2-8°C.

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Benzimidazoles; Benzimidazole is a benzo derivative of imidazole. It is a kind of bicyclic aromatic organic compounds, which is formed by fusing a six-membered benzene ring and five-membered imidazole at positions 4 and 5 of imidazole ring. It is an important pharmacophore of many biologically active heterocyclic compounds with various pharmacological activities. Benzimidazoles and their derivatives have developed into dynamic heterocyclic systems due to their potency in a variety of biologically active compounds such as anticancer, bactericidal and antiviral drugs. Benzimidazoles are a class of therapeutic motifs with broad relevance in medicinal chemistry.

: Abemaciclib; Lilly announced the five-year results of a pre-planned analysis of Phase 3 MonarchE study, which evaluated two years of adjuvant Verzenio® (Abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. Abemaciclib is the first and only CDK4/6 inhibitor approved for the treatment of node-positive, high-risk early breast cancer (EBC) patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.